Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 5/20 | 0.44 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827669 | 0.88 | IDH2 (0.47) | IDH2CTSCABCG2KIF11FLT1 | |
| SCHEMBL827744 | 0.85 | MAPT (0.47) | IDH2CTSCABCG2KIF11FLT1 | |
| SCHEMBL827752 | 0.85 | IDH2 (0.44) | IDH2CTSCABCG2KIF11FLT1 | |
| SCHEMBL827754 | 0.84 | IDH2 (0.46) | IDH2CTSCABCG2KIF11FLT1 | |
| SCHEMBL827545 | 0.83 | AURKA (0.48) | IDH2CTSCABCG2KIF11FLT1 | |
| SCHEMBL10185924 | 0.82 | TRPV4 (0.47) | IDH2FLT1KDRMAPTLMNA | |
| SCHEMBL829454 | 0.81 | IDH2 (0.43) | IDH2CTSCABCG2FLT1FLT4 | |
| SCHEMBL827743 | 0.81 | IDH2 (0.42) | IDH2CTSCABCG2KIF11FLT1 | |
| SCHEMBL827937 | 0.80 | LMNA (0.43) | IDH2FLT1KDRAURKALMNA | |
| SCHEMBL860825 | 0.79 | LMNA (0.52) | IDH2CTSCABCG2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143419-B2 | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA N. V. (BE) | 2012-03-27 | — | — | US | disclosed |
| US-8143419-B2 | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA N. V. (BE) | 2012-03-27 | — | — | US | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | CHRNA1, CHRNA5, CHRNA3 | IDH2 3285/4885CTSC 1824/4885ABCG2 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.